Umecrine Cognition is developing a completely new type of drug for neurological disorders in the brain that can occur as a result of a number of underlying diseases and lead to severely reduced cognition and alertness.
Umecrine Cognition is developing a completely new type of drug for neurological disorders in the brain that can occur as a result of a number of underlying diseases and lead to severely reduced cognition and alertness.
The lead product candidate, golexanolone, is a novel small molecule GABAA receptor-modulating steroid antagonist in development for the treatment of neurological disorders caused by overactivation of GABA-A receptors by the neurosteroid allopregnanolone.
Read more about Umecrane here